Neurological & Neuromuscular
Also called FXS, Martin-Bell Syndrome
Fragile X Syndrome results from expanded CGG trinucleotide repeats in the FMR1 gene on the X chromosome, leading to gene silencing and absence of the fragile X mental retardation protein. This protein plays a critical role in regulating synaptic plasticity and dendritic spine development in the brain.
Fragile X Syndrome affects males more severely than females, with males often showing intellectual disability and females typically displaying milder learning difficulties. The condition affects all ethnic and racial groups equally. The genetic mutation can be inherited from mothers or arise as new mutations. Females who are carriers may experience symptoms ranging from none to moderate intellectual disability.
Multiple clinical trials are investigating targeted treatments for Fragile X Syndrome, including GABA pathway modulators, mGluR5 antagonists, and approaches targeting synaptic plasticity. Promising research focuses on restoring FMRP function through gene therapy and antisense oligonucleotides. Behavioral and educational interventions remain essential, with trials exploring their optimization in combination with pharmacological approaches. Families should consult their neurologist or geneticist about trial eligibility and the latest treatment advances.
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...
Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...
Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...